Bioengineers from Georgia Institute of Technology, Atlanta, Georgia, US have invented a flow-diverter system that offers an effective treatment for aneurysm with active monitoring of intra-aneurysmal haemodynamics.
Three-dimensional (3D) printing shows promise in elucidating answers in the management of complex birth defects, assists in the planning of complex surgical procedures and facilitates stroke rehabilitation, but is beset with various challenges.
Computer and electrical engineers from The State University of New Jersey, US recently designed a cell counting platform that can be integrated with a wristband with readouts linkable to a mobile phone application.
The use of a wearable cardioverter-defibrillator (WCD) may be a suitable alternative for paediatric patients with life-threatening ventricular arrhythmias who are not candidates for implantable cardioverter-defibrillators (ICDs), a recent study showed.
A nasal device that reduces the ability to smell can lead to weight loss and changes in dietary preference for sweet stuff in adults younger than 50 years with obesity, suggesting a novel approach to managing obesity, according to a pilot study presented at the recent European Congress on Obesity (ECO) in Vienna, Austria.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Psychiatry - Malaysia digital copy today!
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.